Form 4 for DXCM Dexcom
Accepted 2025-09-09 00:00:00 ET · period of report 2025-09-05 · accession 0001093557-25-000253 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-09-09 | 2025-09-05 | DXCM | Malady Kyle | Dir | S - Sale | $80.86 | -667 | 22.7K | -3% | -$53.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-09-05 | S | D | 667 | $80.86 | 22,667 | D | — | — | (F1) On June 6, 2025, Mr. Malady adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Malady. The shares set forth above were sold pursuant to the 10b5-1 Plan. (F2) Included in this number are 5,192 unvested restricted stock units which were granted on May 8, 2025 and shall vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2026 Annual Meeting of Stockholders. |